News Updates
More Articles
- Benefits of Integrating Patient Engagement with Diversity, Equity, and Inclusion in New Medical Product Development: A Call for Action
- Drug Shortages in the Global South: A Proposed Parallel Tech and Reg Transfer Framework
- Fair Pay for Patient Engagement: Navigating the Evolving Landscape of Remuneration
- Industry’s Window to Express Interest in Africa Continental Product Evaluation Pilot Closes End of February 2024
- The Importance of Regulatory Due Diligence During the Acquisition Process
Is It Time to Screen for and Treat Early Multiple Myeloma?
Multiple myeloma (MM) is a blood cancer that evolves from the early precursor conditions of monoclonal gammopathy of undetermined significance (MGUS). This article discusses why early detection matters, who should be screened, and the need for precise risk stratification.
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!